A New Combination Therapy Approach

The Phase 3 clinical trial NRG-GY035 (NCT07198074), led by the National Cancer Institute (NCI), has officially begun enrolling patients. This trial evaluates an innovative treatment strategy that combines immunotherapy and anti-angiogenic therapy with standard chemotherapy for patients with mismatch repair proficient (pMMR), TP53-mutant progressive or recurrent endometrial cancer. Merck (Merck & Co., Inc., MRK)'s PD-1 inhibitor Keytruda (pembrolizumab) and Roche (Roche Holding AG, RHHBY)'s VEGF-A inhibitor Avastin (bevacizumab) are being used in combination to overcome the limitations of current standard treatments. This trial represents a significant step toward precision medicine for a difficult-to-treat patient population.

Clinical Context of Target Population

The key target population for this trial, pMMR endometrial cancer patients, typically show a relatively low response rate to monotherapy with immunotherapy compared to mismatch repair deficient (dMMR) patients. In particular, TP53 gene mutations are a well-known biomarker that increases tumor aggressiveness and worsens prognosis, with very limited treatment options. Although the FDA recently approved immunotherapy combinations for both dMMR and pMMR endometrial cancer patients, additional drug combinations are still needed to prolong treatment response duration and maximize survival benefits. This trial aims to achieve a synergistic effect by adding an anti-angiogenic agent to block tumor nutrient supply, thereby improving the tumor microenvironment and maximizing immune response.

Multi-Agent Combination Therapy with Diverse Mechanisms

The study directly compares the efficacy of a three-drug regimen (carboplatin + paclitaxel + pembrolizumab) with a four-drug regimen that includes bevacizumab. Carboplatin and paclitaxel attack cancer cells by forming DNA crosslinks and inhibiting microtubule division, respectively, while pembrolizumab enhances immune cell activity against cancer cells. The addition of bevacizumab, which blocks blood vessel formation and physically suppresses tumor growth, creates a multi-pronged attack on cancer cells. Given that this combination involves flagship products from two major pharmaceutical companies, balancing toxicity management and therapeutic efficacy will be a key determinant of the trial's success.

Paradigm Shift in Treatment and Market Outlook

If the four-drug combination therapy demonstrates a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) compared to existing treatments, it will undoubtedly cause a major shift in first-line treatment guidelines for endometrial cancer. The global endometrial cancer treatment market is projected to reach approximately $31 billion to $33.7 billion by 2025–2026 and is expected to exceed $50 billion by the mid-2030s. As treatment paradigms evolve from single-target approaches to precision medicine-based combination therapies, Merck and Roche's revenue portfolios are expected to become more robust upon new drug approvals. This trial could also serve as a catalyst for the adoption of optimized combinations of immunotherapy and targeted therapies as standard care.